Company intelligence / Profile preview

Soricimed Biopharma Inc.

Moncton, New Brunswick, Canadasoricimed.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 1

Overview

Lead drug candidate SOR-C13 has completed Phase 1 trials showing safety and tolerability with indications of efficacy. Currently in Phase 1b investigator-initiated trial at MD Anderson Cancer Center. SOR-C13 has received FDA orphan drug status for pancreatic and ovarian cancers.

Therapeutic areas: GastroenterologyOncologyWomen's Health
Modalities: PeptidesPeptide-Drug Conjugates (PDCs)Peptide Receptor Radionuclide Therapy (PRRT)
Industry: Biotech

Drug pipeline

3 assets

SOR-C13

2 more assets in the full pipeline.

Request access →

Partnerships

Eisai Inc. (previous collaboration)

Beyond the preview

Go deeper on Soricimed Biopharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soricimed Biopharma Inc..

Explore the full profile